JAGX - Public offerings

Primary endpoint based on patient reported outcomes from study expected in October 2023With the completion of the PIPE financing of unregistered shares and 6-month lock up term, Jaguar has agreed, as described below, not to issue additional equity securities before October 22, 2023 - by which point the Company expects to have released top line data for the OnTarget trialSAN FRANCISCO, CA / ACCESSWIRE / May 9, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that it has completed enrolling the target number of 256 patients in the Company's global, pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients rec

Participating investors include Jaguar CEO and CFO, Dragon SPAC S.p.A. sponsor Josh Mailman, and plant-based pharmaceutical manufacturing pioneer Indena S.p.A.Company to host investor webcast Monday, September 20th at 8:30 a.m. Eastern Click here to register for webcastSAN FRANCISCO, CA / ACCESSWIRE / September 14, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that it completed a $776,200 unregistered private placement of approximately 309,242 shares of Common Stock on September 14, 2021. The private placement was led by New York City-based impact investor Josh Mailman, who is the sponsor of Dragon SPAC S.p.A. and a long-time investor in the Company, an

Napo EU, the identified target of Dragon SPAC, seeks to develop plant-based crofelemer to potentially treat orphan disease - short bowel syndrome (crofelemer has received orphan-drug designation from the US FDA for SBS)Merger of Napo EU & Dragon SPAC expected to be effective within approximately 80 days, with related future SBS license and milestone fees totaling up to $12.5 millionMILAN, ITALY and SAN FRANCISCO, CA / ACCESSWIRE / July 19, 2021 / Dragon SPAC S.p.A. and Napo EU S.p.A., the Italian subsidiary of Napo Pharmaceuticals, Inc., which is the wholly owned U.S. subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX), today announced the closing of the financing of Dragon SPAC for gross procee

Napo EU S.p.A., named target of Dragon SPAC, provides update on plan to pursue conditional marketing authorization for crofelemer in EUEquita Group S.p.A., a leading Italian based investment bank, advising Dragon SPAC; Cantor Fitzgerald & Co. advising Jaguar on non-deal related activitiesSAN FRANCISCO, CA & MILAN, ITALY / ACCESSWIRE / June 1, 2021 / Jaguar Health, Inc. ("Jaguar") and Milan, Italy-based Dragon SPAC S.p.A. ("Dragon SPAC") today announced the initial funding of the private financing of Dragon SPAC, which has named as its target Napo EU S.p.A. ("Napo EU"). Dragon SPAC and Napo Pharmaceuticals, Inc. ("Napo Pharma"), Jaguar's wholly-owned U.S. subsidiary, have entered into an agre

Company terminates at-the-market (ATM) financing programSAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement (the "Transaction") with North American institutional investors for the purchase and sale of 7,647,000 shares of common stock for gross proceeds of approximately $10.8 million in a registered direct offering.Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent in connection with the Transaction. The closing of the offering is expected to take place on or about May 3, 2021 (the "Closing Date"), subject to the satisfaction or waiver of customary

No royalty payments due for 36 months Company has started to identify key opinion leader physicians in the US as well as Europe focused on addressing the symptoms - including gastrointestinal distress - that afflict a significant proportion of COVID-19 survivors for an extended period after recovery SAN FRANCISCO, CA / ACCESSWIRE / March 9, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has signed the definitive agreement (the "Agreement") related to the previously announced term sheet for a third non-dilutive royalty financing transaction, pursuant to which Jaguar is selling to the lender for an aggregate purchase price of $5 million

No royalty payments due for 36 months Planned COVID-related indication in long-hauler patients is the lead focus for crofelemer at Napo EU, the exclusive target of the planned Dragon SPAC, which is pursuing listing on AIM Italia Company expects to provide additional updates regarding Napo EU next week SAN FRANCISCO, CA / ACCESSWIRE / March 5, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has entered a binding agreement of terms (the "Term Sheet") for a third non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the lender for an aggregate purchase price of $5 million (the "Royalty Purchase Price") a royal

This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients and severe acute watery diarrhea SAN FRANCISCO, CA / ACCESSWIRE / January 20, 2021 /  Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has signed a definitive agreement (the "Agreement") related to the previously announced term sheet for the issuance and sale of a secured promissory note in the principal amount of $6.0 million (the "Note") to Streeterville Capital, LLC (the "Investor"). The sale of the Note closed on January 19, 2021. Per the terms of the Agreement, in

SAN FRANCISCO, CA / ACCESSWIRE / January 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided the replay link for the Company's January 14, 2021 investor webcast and a recap of the key points from the presentation. To access the audio recording and slides from the webcast, click here. "Due to the unprecedented volume of participants for yesterday's webcast, a number of parties were unable to join the live event," stated Lisa Conte, Jaguar's founder, president, and CEO. "In light of this, we want to make sure investors know that the event audio recording and the corresponding slides can be accessed on the investor relations section of Jaguar's website at

SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement with two institutional investors including a high-net-worth family office for the purchase and sale of 4,437,870 shares of common stock at a purchase price of $3.38 per share for gross proceeds of approximately $15.0 million in a registered direct offering priced above-the-market under Nasdaq rules. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent in connection with the offering. The closing of the offering is expected to take place on or about January 15, 2021, subject to the satisfaction o